Truist on Roivant (ROIV): 'we could see confidence grow over time with increasing script volumes'
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $19.00 price target on Roivant Sciences (NASDAQ: ROIV).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
